Fulcrum appoints industry veteran as new CMO

© Reuters.

CAMBRIDGE, Mass. – Fulcrum Therapeutics, Inc. (NASDAQ:), a clinical-stage biopharmaceutical company, announced today the immediate appointment of Dr. Patrick Horn as Chief Medical Officer (CMO). Dr. Horn brings over two decades of experience in drug development, particularly in rare diseases, to Fulcrum’s leadership team.

The company, which is currently advancing its Phase 3 REACH trial of losmapimod for facioscapulohumeral muscular dystrophy (FSHD), and reinitiating its Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD), expects Dr. Horn’s expertise to be crucial in navigating the upcoming regulatory submissions and approvals.

Dr. Horn’s career includes roles as CMO at HemoShear Therapeutics and Albireo Pharma (NASDAQ:), where he was instrumental in obtaining marketing approvals in the US and Europe for Bylvay™ in progressive familial intrahepatic cholestasis (PFIC). His tenure also includes senior positions at Orphan Technologies and Tetraphase (NASDAQ:) Pharmaceuticals, contributing to the approval of therapeutics such as Kalbitor® for hereditary angioedema.

Iain Fraser, MBChB, DPhil, who has been serving as Interim CMO, will continue as Senior Vice President (SVP) of Early Development. Together, Drs. Horn and Fraser are tasked with leading clinical development and overseeing regulatory strategy.

Alex C. Sapir, Fulcrum’s President and CEO, expressed confidence in Dr. Horn’s ability to guide the company’s key clinical programs through crucial milestones. Dr. Horn himself underscored the potential of Fulcrum’s therapies to transform patient care, particularly highlighting losmapimod’s first-to-market potential and pociredir’s promise as a differentiated oral treatment.

Fulcrum’s focus remains on developing treatments for genetically defined rare diseases with high unmet medical needs, leveraging their proprietary technology to modulate gene expression and address the root cause of gene mis-expression.

The information in this article is based on a press release statement from Fulcrum Therapeutics. The company cautions that the forward-looking statements contained in the press release involve risks and uncertainties that may affect their actual results, including the advancement of product candidates in clinical trials, regulatory approvals, and the raising of additional capital.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.